BARD1
- Known as:
- BARD1
- Catalog number:
- 002411A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- BARD1
Related genes to: BARD1
- Gene:
- BARD1 NIH gene
- Name:
- BRCA1 associated RING domain 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1998-08-05
- Date modifiied:
- 2019-04-23
Related products to: BARD1
Related articles to: BARD1
- This study aims to investigate the mutational spectrum of and genes in a cohort of breast cancer (BC) patients from southern Tunisia, and to evaluate their clinical and prognostic significance. Additionally, this study explores the contribution of other cancer predisposition genes and the prevalence of variants of uncertain significance (VUS). - Source: PubMed
Publication date: 2026/08/29
Ammous-Boukhris NihelAbdelmaksoud-Dammak RaniaBen Kridis WalaBen-Ayed-Guerfali DorraGuidara SouhirFeki AmeniKamoun HassenKhanfir AfefDaoud JamelLizard Gérard-HubertGargouri AliMokdad-Gargouri Raja - Breast cancer remains highly prevalent, where the lifetime risk before age 75 is one in 13. However, known genetic factors were only identified in 14.7% of cases in our Hong Kong Hereditary Breast Cancer Family Registry. Our current local policy for genetic testing does not cover the detection of beyond . Here we highlight the clinical value of extending testing to beyond susceptibility genes for improved prevention, diagnosis, and management. We recruited 6597 hereditary breast and ovarian cancer (HBOC) patients from our registry based on family history and clinical criteria. Germline mutations were identified by multi-gene sequencing analysis using next-generation sequencing (NGS). Clinical-pathological characteristics of and beyond carriers were compared and the real-world management and surveillance services adopted in Hong Kong were highlighted. In this multi-gene hereditary cancer cohort, germline mutations were identified in 10.9% of cases for and 3.5% for beyond susceptibility genes. These beyond mutations constitute a considerable proportion of actionable hereditary risk. Notably, emerged as the most prevalent non- gene, followed by , , and . New cancers or recurrences were detected during their surveillance; the overall pick up rates were 8.3% (), 29.4% (), 33.3% () and 5.6% (). This study provides the first comprehensive characterization of the beyond germline landscape in a Hong Kong hereditary cancer cohort and highlights the current need for implementing multi-gene sequencing analysis and surveillance services for HBOC patients, establishing the predominant non- drivers and providing a robust empirical basis for expanding public genetic screening frameworks. - Source: PubMed
Publication date: 2026/08/24
Kwong AvaHo Cecilia Y STey Sze KeongAu Chun HangMa Edmond S K - Ovarian cancer is one of the leading causes of death from gynecological cancer worldwide. Genetic mutations in genes involved in key cellular functions such as BRCA1/2 play a central role in tumorigenesis and have major implications for targeted therapeutic strategies, especially the use of poly (ADP-ribose) polymerase (PARP) inhibitors. - Source: PubMed
Ammous-Boukhris NihelAbdelmaksoud-Dammak RaniaFeki AmeniKhemiri SouhirCharfi SlimSallemi-Boudawara TahiaDaoud JamelKhanfir AfefGargouri Raja Mokdad - The tumor suppressor protein breast cancer type 1 susceptibility protein (BRCA1) plays a central role in maintaining genome stability through its involvement in DNA damage repair, transcriptional regulation, and cell-cycle control. BRCA1 functions as an obligate heterodimer with its binding partner, the BRCA1-associated RING domain protein 1 (BARD1), to coordinate accurate DNA repair. While the structured N- and C-terminal domains of BRCA1 have been well-characterized, the large central region encoded largely by exon 11 that comprises ~ 80% of the protein, is intrinsically disordered, and remains poorly structurally characterized. This intrinsically disordered region (IDR) harbors critical interaction interfaces for key proteins involved in genome maintenance, including RAD50, RAD51, MYC, and RB. Here, we report the backbone resonance assignments of a BRCA1 IDR construct spanning residues 467-696, providing a foundation for future studies aimed at understanding how the disordered central region of BRCA1 contributes to homologous recombination, interactions with BARD1, and overall BRCA1 tumor suppressor function. - Source: PubMed
Publication date: 2026/09/04
Dinh Hoang HJasper Angela MBaudin AntoineSung PatrickLibich David S - The BRCA1-associated RING domain protein 1 (BARD1) is the obligate binding partner of the tumor suppressor breast cancer type 1 susceptibility protein (BRCA1) and plays a critical role in maintaining genome integrity. BARD1 contains structured N- and C-terminal domains that mediate heterodimerization with BRCA1, recognition of chromatin marks, and DNA repair functions. Approximately 40% of BARD1 is intrinsically disordered, particularly in the central region of the protein. This intrinsically disordered region (IDR) engages DNA and key repair proteins such as RAD51, BLM, and WRN. DNA binding through the BARD1 IDR facilitates H2A ubiquitination by the BRCA1-BARD1 complex and is essential for stimulating long-range DNA end resection during homologous recombination, underscoring its role in accurate DNA repair. Despite these insights, structural characterization of the IDR remains limited, leaving questions regarding its functional interplay with BRCA1 and other repair factors unresolved. Here, we report the backbone resonance assignments of a BARD1 IDR construct spanning residues 124-270, providing a foundation for future studies aimed at understanding how the disordered regions of BARD1 interact with various binding partners, and cooperates with itself and BRCA1 to regulate genome stability. - Source: PubMed
Publication date: 2026/09/01
Dinh Hoang HJasper Angela MBaudin AntoineSung PatrickLibich David S